1
Return

Impact of Sample Type on ADAP-Based Autoantibody Detection for Type 1 Diabetes Population Screening

delete2025-11-04
delete0
delete
OA
AI
I
Inés Urrutia
M
Maitane González-Arceo
B
Begoña Calvo
J
Josu Aurrekoetxea-Oribe
E
Elsa Fernández-Rubio
V
Virginia Urquijo
B
Bilbao, Jose Ramon
I
Itxaso Rica
L
Luís Castaño
R
Rosa Martı́nez *
DOI:10.1177/15209156251390835delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Context: The growing worldwide interest in early-stage type 1 diabetes (T1D) screening highlights the need for efficient and affordable approaches. Advanced analytical technologies such as Antibody Detection by Agglutination-PCR (ADAP) have improved large-scale sample handling, but optimal sample selection for simplified collection and processing remains a major challenge in screening designs. Objective: To assess ADAP for T1D-related autoantibody detection in different blood-derived samples to select the optimal sample type for large-scale screening. Methods: Autoantibodies against insulin (IAA), glutamate decarboxylase (GADA), protein tyrosine phosphatase IA-2 (IA2A), and zinc transporter 8 (ZnT8A) were analyzed by ADAP in 171 patients with stage 3 T1D (13.7 years; interquartile range [IQR]: 6.5–15.0) and 95 healthy controls (41.9 years; IQR: 29.5–56.7) previously studied by radiobinding assay (RBA). Comparison of sensitivity/specificity of ADAP and RBA in serum was assessed, as well as ADAP concordance across serum, plasma, EDTA-anticoagulated whole blood, and dried blood spot (DBS). Whole-blood stability was also investigated. Results: ADAP-based detection of two or more autoantibodies in serum demonstrated high sensitivity (87.1%) and specificity (100%), with strong concordance with RBA (Cohen’s kappa 0.90). Autoantibody analysis in whole blood by ADAP showed high agreement with serum, making it a consistent alternative. In contrast, DBS sampling had reduced concordance, which led to fewer positive detections and suggests a potential bias for T1D screening. A remarkable advantage was that autoantibodies in unrefrigerated whole blood remained stable for up to 7 days (IAA) and 20 days (GADA, IA2A, and ZnT8A), and also after four freeze–thaw cycles, considerably simplifying logistics. Conclusion: Pancreatic autoantibody detection in whole blood with ADAP provides a stable and more efficient diagnostic solution for T1D population screening, with simplified preparation, low-volume requirements, and high diagnostic consistency comparable with serum-based assays.
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Diabetes Technology and Therapeutics cover
Diabetes Technology and Therapeutics
IF:
6.3
Papers:
2.9K
Citations:
7.5K

Organization

No organization information available
Cited Papers

Cited Papers

Citing Papers

Citing Papers